Novo Nordisk, Eli Lilly poised to divvy up obesity market that could be worth $50B in 2030: analysts

While reimbursement and education challenges persist, drugmakers like Eli Lilly and Novo Nordisk are poised to unlock a global obesity market that could be worth more than $50 billion by the end of the decade, analysts at Morgan Stanley Research wrote in a note to clients Friday.